Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maris

Showing results (121-130 of 458) with videos related to

Pageof 46
Sort By:
Pediatric Blood & Cancer|September 5, 2009
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroHolly J Meany, Dan L Sackett, John M Maris, et al.
Bioinformatics (Oxford, England)|February 11, 2025
ImmunoTar-integrative prioritization of cell surface targets for cancer immunotherapyRawan Shraim, Brian Mooney, Karina L Conkrite, et al.
Genomics|May 15, 1997
An integrated transcript map of human chromosome 1p35-p36S J Jensen, E P Sulman, J M Maris, et al.
Genes, Chromosomes & Cancer|July 25, 2007
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expressionYael P Mosse, Sharon J Diskin, Nora Wasserman, et al.
Genome Research|August 11, 2006
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experimentsSharon J Diskin, Thomas Eck, Joel Greshock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group studyLisa A Moreau, Patrick McGrady, Wendy B London, et al.
Cell Cycle (Georgetown, Tex.)|February 21, 2014
Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cellsYuko Murakami-Tonami, Satoshi Kishida, Ichiro Takeuchi, et al.
Cytogenetics and Cell Genetics|August 6, 1998
Physical mapping of the CA6, ENO1, and SLC2A5 (GLUT5) genes and reassignment of SLC2A5 to 1p36.2P S White, S J Jensen, V Rajalingam, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Advancing childhood cancer research through young investigator and advocate collaborationAmber K Weiner, Antonia Palmer, Melanie Frost Moll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group studyRani E George, Wendy B London, Susan L Cohn, et al.
Pageof 46

Showing results (121-130 of 458) with videos related to

Sort By:
Pageof 46
Pediatric Blood & Cancer|September 5, 2009
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroHolly J Meany, Dan L Sackett, John M Maris, et al.
Bioinformatics (Oxford, England)|February 11, 2025
ImmunoTar-integrative prioritization of cell surface targets for cancer immunotherapyRawan Shraim, Brian Mooney, Karina L Conkrite, et al.
Genomics|May 15, 1997
An integrated transcript map of human chromosome 1p35-p36S J Jensen, E P Sulman, J M Maris, et al.
Genes, Chromosomes & Cancer|July 25, 2007
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expressionYael P Mosse, Sharon J Diskin, Nora Wasserman, et al.
Genome Research|August 11, 2006
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experimentsSharon J Diskin, Thomas Eck, Joel Greshock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group studyLisa A Moreau, Patrick McGrady, Wendy B London, et al.
Cell Cycle (Georgetown, Tex.)|February 21, 2014
Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cellsYuko Murakami-Tonami, Satoshi Kishida, Ichiro Takeuchi, et al.
Cytogenetics and Cell Genetics|August 6, 1998
Physical mapping of the CA6, ENO1, and SLC2A5 (GLUT5) genes and reassignment of SLC2A5 to 1p36.2P S White, S J Jensen, V Rajalingam, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Advancing childhood cancer research through young investigator and advocate collaborationAmber K Weiner, Antonia Palmer, Melanie Frost Moll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group studyRani E George, Wendy B London, Susan L Cohn, et al.
Pageof 46